Home » Topics » BioWorld Science

BioWorld Science
RSS

Idorsia initiates phase III study of aprocitentan for resistant hypertension

June 20, 2018

Kala updates registration plan for KPI-121 for short-term treatment of dry eye disease

June 20, 2018

Can-Fite updates status of phase II trial of namodenoson in advanced HCC

June 20, 2018

Seattle Children's initiates phase I trial of CAR T-cell therapy for pediatric CNS tumors

June 20, 2018

Monalizumab shows promising activity in combination with durvalumab in MSS-CRC

June 20, 2018

Andes-1537 well tolerated in phase I study, dose expansions planned

June 20, 2018

Genentech, Roche and Paraza Pharma patent TRPA1 antagonists

June 20, 2018

Allena Pharmaceuticals completes preclinical proof-of-concept study for ALLN-346

June 20, 2018

Boehringer Ingelheim identifies free fatty acid receptor 1 agonists

June 20, 2018

RC-48-ADC demonstrates promising antitumor activity in patients with metastatic breast cancer

June 20, 2018

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...